Finoriq research workspace
ABEONA THERAPEUTICS INC. (ABEO) Historical Metrics
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell. Review ABEO valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
- Company
- ABEONA THERAPEUTICS INC. (ABEO)
- Ticker
- ABEO
- Market Cap
- $368.2M
- Latest Price
- $6.46
- Industry
- Biotech & Pharma
ABEONA THERAPEUTICS INC. (ABEO) Current Valuation Metrics
Static valuation preview for ABEONA THERAPEUTICS INC. (ABEO). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 6.15x | Net Income | TTM Q1 2026 |
| P/SMarket cap divided by latest TTM revenue. | 28.0x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 16.3% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -19.1% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 2.81x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.